Abstract
A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe bone marrow depression during Ra radionuclide therapy. Because of this, he was treated with Lu-PSMA in compassionate use for this not-yet-approved therapy. At the beginning of Lu-PSMA therapy, repeated blood transfusions (BT) were necessary. Six months after the last BT, after 3 cycles of Lu-PSMA, his blood count stabilized. He required no further BTs and his PSA level remained lowered.
MeSH terms
-
Aged
-
Anemia / chemically induced
-
Anemia / drug therapy
-
Antineoplastic Agents / adverse effects
-
Bone Marrow Diseases / chemically induced
-
Bone Marrow Diseases / drug therapy*
-
Bone Neoplasms / diagnostic imaging
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / secondary
-
Compassionate Use Trials
-
Dipeptides / therapeutic use*
-
Edetic Acid / analogs & derivatives
-
Gallium Isotopes
-
Gallium Radioisotopes
-
Heterocyclic Compounds, 1-Ring / therapeutic use*
-
Humans
-
Lutetium
-
Male
-
Oligopeptides
-
Positron Emission Tomography Computed Tomography
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms, Castration-Resistant / blood
-
Prostatic Neoplasms, Castration-Resistant / drug therapy*
-
Prostatic Neoplasms, Castration-Resistant / pathology
-
Radioisotopes / adverse effects
-
Radionuclide Imaging
-
Radiopharmaceuticals
-
Radium / adverse effects
-
Technetium Tc 99m Medronate
Substances
-
177Lu-PSMA-617
-
Antineoplastic Agents
-
Dipeptides
-
Gallium Isotopes
-
Gallium Radioisotopes
-
Heterocyclic Compounds, 1-Ring
-
Oligopeptides
-
Radioisotopes
-
Radiopharmaceuticals
-
gallium 68 PSMA-11
-
Lutetium
-
Edetic Acid
-
Prostate-Specific Antigen
-
radium Ra 223 dichloride
-
Radium
-
Technetium Tc 99m Medronate